WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
Erin
Sparrow
;
Ifedayo
Adetifa
;
Nathorn
Chaiyakunapruk
;
Thomas
Cherian
;
Deshayne B
Fell
;
Barney S
Graham
;
Bruce
Innis
;
David C
Kaslow
;
Ruth A
Karron
;
Harish
Nair
;
+7 more...
Kathleen M
Neuzil
;
Samir
Saha
;
Peter G
Smith
;
Padmini
Srikantiah
;
Fred
Were
;
Heather J
Zar
;
Daniel
Feikin
;
(2022)
WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
Vaccine, 40 (26).
pp. 3506-3510.
ISSN 0264-410X
DOI: 10.1016/j.vaccine.2022.02.040
World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies.
Item Type | Article |
---|---|
Elements ID | 170573 |
Date Deposited | 10 Jun 2022 15:01 |
ORCID: https://orcid.org/0000-0003-2556-9407
ORCID: https://orcid.org/0000-0003-0080-7560